Company Analysis
Sign in

PDS Biotechnology Corporation (PDSB)

Nasdaq: PDSB · Pharmaceutical Preparations · Princeton, NJ · filing with the SEC since 2009
Full chart Alerts Compare
Grade5.0
◀ Past 4.7● Present 3.8▶ Future 6.3
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$34.5M+8.3%
Earnings per share$-0.74+28.2%
Operating cash flow-$27.8M+20.8%
Cash$26.7M-35.9%
Debtn/a
Shareholders’ equity$22.4M+17.7%
Shares, diluted46.4M+27.2%
Return on equity-372.8%
The recordfrom its filings
Filings in 202667
Newest filingNov 12 · SCHEDULE 13D/A
Annual reportMar 30, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted19
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$33.7MCash from operations -$16.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 21, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PDSB · research, not advice